基于的抑制剂在破坏针对癌症治疗的蛋白质-蛋白质相互作用方面的潜力
Alexandra L Afonso1, Catarina T Cavaleiro1, Miguel A R B Castanho1,2
1Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
International journal of molecular sciences
|April 17, 2025
概括
类抑制剂通过向瘤原蛋白-蛋白相互作用 (OncoPPIs) 为癌症治疗提供了一个有前途的新策略. 与传统的小分子相比,这些具有较高的特异性和较低的毒性.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白与蛋白相互作用 (PPI) 形成细胞相互作用体,对生物过程至关重要.
- 失调的PPI,或瘤性PPI (OncoPPI),驱动癌症的发展和扩散.
- 向OncoPPI是开发新型癌症疗法的关键策略.
研究的目的:
- 审查针对癌症的PPI的关键方面.
- 强调OncoPPI在癌症治疗中的重要性.
- 探索基于的抑制剂对癌症治疗中小分子的优势.
主要方法:
- 关于PPI抑制和治疗的当前文献的综述.
- 分析抑制剂的优点,包括特异性,毒性和可修改性.
- 讨论突破设计的进展,以克服治疗限制.
主要成果:
- 基于的抑制剂为PPI抑制提供了小分子的令人信服的替代品.
- 具有高特异性,低毒性和易于修改等优点.
- 最近在酸设计方面的进展解决了这些局限性,提高了它们的治疗潜力.
结论:
- 基于的抑制剂是一种有前途的治疗策略,用于向癌症性PPI治疗癌症.
- 酸设计的进一步进步可能会扩大它们在向癌症治疗中的作用.
- 本综述提供了针对癌症治疗的抑制剂的全面概述.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


